An interventional study of Support-t in Diabetes Mellitus, Diabetes Mellitus, Type 1 and Glucose Metabolism Disorders (Including Diabetes Mellitus), sponsored by Anne-Sophie Brazeau. Active, not recruiting at 4 sites in Canada. Open to participants aged 14 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Anne-Sophie Brazeau · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 319 studies in Diabetes Mellitus, Type 1 with a site in Canada — 49 open to participants now, 61 under way, 15 of them phase 3. Diabetes Mellitus, Type 1 · Canada.
Among the 319 studies in Diabetes Mellitus, Type 1 with a site in Canada, this one is the 68th largest by planned enrollment of the 275 interventional ones that give a count, is one of 15 that started in 2024, is one of 99 with no phase, reaches primary completion later than 38 of the 60 other live ones, and was the 275th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →49 of the 319 studies in Diabetes Mellitus, Type 1 with a site in Canada are open now. Recruiting first, the newest first:
Institut de Recherches Cliniques de Montreal · Sites in Canada
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
Kriya Therapeutics, Inc. · Sites in Canada, New Zealand
Ages 18–65
Institut de Recherches Cliniques de Montreal · Sites in Canada
Ages 18+ · Healthy volunteers
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada, Switzerland
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 14 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
319 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 79 · Phase 3 70 · Phase 4 12
First in 1983; this study’s year is marked. 15 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 45 across the 275 interventional studies, 205 across the 44 observational. Of the 231 that completed or were terminated, 73 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 319 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Anne-Sophie Brazeau as lead sponsor.
Anne-Sophie Brazeau has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
23 of the studies in Diabetes Mellitus, Type 1 with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06894784Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | 2027-01 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT05762107Zucara Therapeutics Inc.A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | 2026-12 |
| NCT04963777University of CalgaryPrebiotics in Patients With Type 1 Diabetes | 2026-12-01 |
Add all 23 to your calendar (.ics) → With an account.
Among the 319 studies in Diabetes Mellitus, Type 1 with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators will conduct a randomized controlled trial (RCT) to examine how an online training and peer support platform could help the preparation to transition to adult care. Among 14-16 year old youth with Type 1 Diabetes (T1D), the investigators aim to assess the effect of an online training and peer support platform (Support-t) integrated in usual care, compared with usual care on Hemoglobin A1c (HbA1c), adverse outcomes and psychosocial measures during the preparation for transition to adult care. The investigators will conduct a multi-site, parallel group, blinded (outcome assessors, data analysts), superiority RCT of adolescents with T1D (14-16 years of age) followed at one of 4 university teaching hospital-based pediatric diabetes clinics in the province of Quebec.
The transition from pediatric to adult diabetes care is a challenging period for adolescents and young adults living with chronic conditions, such as Type 1 Diabetes (T1D). For youth with T1D, transition from pediatric to adult care is characterized by deterioration in glycemic control (Hemoglobin A1c [HbA1c]), reduced adherence to diabetes management tasks and increased risk of diabetes complications. The investigators propose to examine an online training and peer support platform as a potential alternative for delivering transition care. In adolescents with T1D, the investigators hypothesize that an online training and peer support platform (Support-t), when integrated into usual pediatric care, as compared with usual care alone, will result in better HbA1c, less adverse outcomes and better psychosocial outcomes during the preparation for transfer to adult care.
Primary Aim: To determine the impact of adding access to Support-t to usual care compared with usual care alone, on HbA1c during the preparation for transfer to adult care.
Secondary Aims: To determine the impact of adding access to Support-t to usual care compared with usual care alone, on self-efficacy, diabetes distress, quality of life (QOL; diabetes specific), readiness to transfer to adult care, glucose management, severe hypoglycemic episodes, diabetic ketoacidosis (DKA), T1D-related ED-visits and hospitalizations during the preparation for transfer to adult care. 2. To determine the cost-effectiveness of Support-t. 3. To understand the context for implementation in regards to level of engagement on Support-t, satisfaction and experience (barriers, facilitators) with Support-t.
Methods: The investigators will conduct a multi-site, parallel group, blinded (outcome assessors, data analysts), superiority RCT of adolescents with T1D (14-16 years of age) followed at one of 4 university teaching hospital-based pediatric diabetes clinics in Quebec. Patients will be recruited over 20 months. Interventions will occur over 18 months. Follow-up will be to 18 months from enrollment. Allocation will be concealed with a 1:1 intervention to control ratio. Participants in the active arm will have access to a mobile-based online training and peer support platform (Support-t) added to usual care. Participants in the control group will have in parallel with the intervention group, their usual diabetes care. The primary outcome is the change in HbA1c measured at 18 months (HbA1c measured at 18 months - HbA1c measured at baseline). Secondary outcomes are self-efficacy, diabetes distress, QOL, readiness to transfer, glucose management, severe hypoglycemic episodes, DKA, T1D-related ED-visits and hospitalizations. Assessments are at baseline, 6, 12 and 18 months. Analysis will be by intention-to-treat. Outcomes will be calculated and compared between the 2 trial arms using differences with 95% Confidence Intervals, along with a cost-effectiveness analysis. Interviews will be conducted to analyze the context for implementation.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's planned enrollment of 200 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →This is the only study on the registry with Anne-Sophie Brazeau as lead sponsor.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Access to the Support-t online training and peer support platform in addition to usual diabetes care for 18 months. Support-t contains 3 components: 1) Educational material, 2) News blog and 3) Patients' discussion forum. Health care providers from the pediatric diabetes clinics will receive Support-t training and will be encouraged to recommend the Support-t platform during routine care with their patients from the active arm.
Other: Support-t
Usual diabetes care for 18 months, which consists of visits with their health care provider and ad-hoc diabetes education with nurses and dietitians. Health care providers from the pediatric diabetes clinics will be instructed not to discuss or refer to the Support-t platform with patients from the control arm. Control arm participants will have the option to use the Support-t platform after the 18-month study.
Support-t plus usual diabetes care for 18 months
Change from Baseline Hemaglobin A1c (HbA1c) at 18 months
HbA1c measured with a venous or capillary blood sample as part of the standard of diabetes care will be derived from the medical record chart or measured using an A1c Test Kit, which is a non-fasting, finger prick, whole blood test
Time frame: 18 months
Change from Baseline Hemaglobin A1c (HbA1c) at 6 and 12 months
HbA1c measured with a venous or capillary blood sample as part of the standard of diabetes care will be derived from the medical record chart or measured using an A1c Test Kit, which is a non-fasting, finger prick, whole blood test
Time frame: 6, 12 months
Continuous Glucose Monitoring (CGM) - % Time in range
% Time in range (3.9-10.0mmol/L) over the past 4 weeks will be derived from the medical record chart
Time frame: 0, 6, 12, 18 months
Continuous Glucose Monitoring (CGM) - % Time above range
% Time above range (3.9-10.0mmol/L) over the past 4 weeks will be derived from the medical record chart
Time frame: 0, 6, 12, 18 months
Continuous Glucose Monitoring (CGM) - % Time below range
% Time below range (3.9-10.0mmol/L) over the past 4 weeks will be derived from the medical record chart
Time frame: 0, 6, 12, 18 months
Continuous Glucose Monitoring (CGM) - Standard deviation
Standard deviation of the past 4 weeks will be derived from the medical record chart
Time frame: 0, 6, 12, 18 months
Continuous Glucose Monitoring (CGM) - % Coefficient of variation
% Coefficient of variation of the past 4 weeks will be derived from the medical record chart
Time frame: 0, 6, 12, 18 months
Severe hypoglycemic events
Any severe hypoglycemic events in the past 6 months will be derived from self-report and from the medical record chart
Time frame: 0, 6, 12, 18 months
Diabetic Ketoacidosis (DKA) events
Any Diabetic Ketoacidosis (DKA) events in the past 6 months will be derived from self-report and from the medical record chart
Time frame: 0, 6, 12, 18 months
Diabetes-related hospitalizations
Any diabetes-related hospitalizations in the past 6 months, expressed as number of hospitalizations per person-years (P-Y) at risk will be derived from self-report and from the medical record chart
Time frame: 0, 6, 12, 18 months
Diabetes-related emergency department visits
Any diabetes-related emergency-department visits in the past 6 months, expressed as number of emergency department visits per person-years (P-Y) at risk will be derived from self-report and from the medical record chart
Time frame: 0, 6, 12, 18 months
Self-efficacy
Self-efficacy for Diabetes Self-Management Measure (SEDM) assesses self-efficacy. The score ranges from 1 to 10. All item scores are averaged to compute the score. A higher score represents a better outcome.
Time frame: 0, 6, 12, 18 months
Diabetes distress
Problem Areas in Diabetes Scale-Teen (PAID-T) assesses adolescent diabetes distress. The scores range from 14 to 84. A total distress score is computed by summing responses. Higher scores indicate youth perception of feeling more burdened related to T1D.
Time frame: 0, 6, 12, 18 months
Diabetes specific Quality of Life (QOL)
Type 1 Diabetes and Life (T1DAL) questionnaire assesses diabetes specific QOL for 12-17 year old adolescents living with T1D. Scores are transformed on a scale from 0 to 100. The total score ranges from 0 to 100. To calculate the total score, the mean is computed as the sum of all item scores divided by the number of items answered on all the scales. A higher total score represents a better outcome. The subscale scores (Daily Emotional Experiences \& Daily Activities, Handling Diabetes Well, Peer Relationships, and Family Relationships) range from 0 to 100. To calculate the subscale scores, the mean is computed as the sum of the items in the subscale divided by the number of items answered on the subscale. Higher subscale scores represent a better outcome.
Time frame: 0, 6, 12, 18 months
Transition readiness
Readiness Assessment of Emerging Adults with Type 1 Diabetes Diagnosed in Youth (READDY) assesses diabetes-related knowledge or skill items by querying respondents on 42 total items split into 5 domains: knowledge, navigation, health behaviors, and insulin pump skills. Respondents answer on a Likert scale from "yes, I can do this" scored 5 to "Haven't thought about it" scored 1. Confidence level is evaluated in each domain with a higher score indicating more confidence.
Time frame: 0, 6, 12, 18 months
Cost effectiveness (HbA1c)
Cost effectiveness of access to Support-t in addition to usual care compared with usual care in terms of incremental cost effectiveness ratio (ICER) for HbA1c
Time frame: 12 and 18 months
Cost effectiveness (self-efficacy)
Cost effectiveness of access to Support-t in addition to usual care compared with usual care in terms of incremental cost effectiveness ratio (ICER) for self-efficacy
Time frame: 12 and 18 months
Cost effectiveness (diabetes distress)
Cost effectiveness of access to Support-t in addition to usual care compared with usual care in terms of incremental cost effectiveness ratio (ICER) for diabetes distress
Time frame: 12 and 18 months
Cost effectiveness (QOL)
Cost effectiveness of access to Support-t in addition to usual care compared with usual care in terms of incremental cost effectiveness ratio (ICER) for QOL
Time frame: 12 and 18 months
Engagement with Support-t platform (T1D patient) - time in minutes on platform
Engagement metrics will be extracted using Google analytics - time (minutes) spent on the platform
Time frame: 6, 12, 18 months
Engagement with Support-t platform (T1D patient) - discussion forum participation
Engagement metrics will be extracted using Google analytics - participation on the platform discussion forum
Time frame: 6, 12, 18 months
Engagement with Support-t platform (T1D patient) - content accessed
Engagement metrics will be extracted using Google analytics - specific content accessed from the platform
Time frame: 6, 12, 18 months
Engagement with Support-t platform (T1D patient) - total pages viewed
Engagement metrics will be extracted using Google analytics - total pages viewed from the platform
Time frame: 6, 12, 18 months
Engagement with Support-t platform (T1D patient) - downloaded documents
Engagement metrics will be extracted using Google analytics - downloaded documents from the platform
Time frame: 6, 12, 18 months
Engagement with Support-t platform (T1D patient) - use of calculators
Engagement metrics will be extracted using Google analytics - use of calculators on the platform
Time frame: 6, 12, 18 months
Engagement with Support-t platform (Health Care Provider) - time in minutes on platform
Engagement metrics will be extracted using Google analytics - time (minutes) spent on the platform
Time frame: 6, 12 months
Engagement with Support-t platform (Health Care Provider) - content accessed
Engagement metrics will be extracted using Google analytics - specific content accessed from the platform
Time frame: 6, 12 months
Engagement with Support-t platform (Health Care Provider) - total pages viewed
Engagement metrics will be extracted using Google analytics - total pages viewed from the platform
Time frame: 6, 12 months
Engagement with Support-t platform (Health Care Provider) - downloaded documents
Engagement metrics will be extracted using Google analytics - downloaded documents from the platform
Time frame: 6, 12 months
Engagement with Support-t platform (Health Care Provider) - use of calculators
Engagement metrics will be extracted using Google analytics - use of calculators on the platform
Time frame: 6, 12 months
Satisfaction with Support-t platform - T1D patient
Satisfaction will be rated on a scale from 1 to 10. Higher scores indicate greater satisfaction with the platform.
Time frame: 6, 12, 18 months
Experience with Support-t platform (Barriers, facilitators, satisfaction, fidelity) - T1D patient
Individual interviews to understand the experience in the context of implementation of the Support-t platform (Barriers, facilitators, satisfaction, fidelity) using qualitative descriptive methodology
Time frame: 18 months
Experience with Support-t platform (Barriers, facilitators, satisfaction, fidelity) - Health Care Provider
Individual interviews to understand the experience in the context of implementation of the Support-t platform (Barriers, facilitators, satisfaction, fidelity) using qualitative descriptive methodology
Time frame: 12 months
Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 35 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Apr 2027 → Sep 2027 and completion Oct 2027 → Jan 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.